NT-0796

DRUG3 trials

Sponsors

NodThera Limited, Rezera (formerly NodThera Limited)

Conditions

Cardiovascular DiseasesObesityObesity and Type 2 Diabetes

Phase 1

Effects of NT-0796 in Obese Participants at Risk of Cardiovascular Disease

CompletedNCT06129409

NodThera LimitedCardiovascular Diseases

Start: 2023-10-10End: 2024-04-15Updated: 2024-12-16

Phase 2

Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus

CompletedNCT07055516

Rezera (formerly NodThera Limited)Obesity and Type 2 Diabetes

Start: 2025-05-08End: 2026-05-27Updated: 2026-09-15

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

CompletedNCT07220629

Rezera (formerly NodThera Limited)Obesity

Start: 2025-10-02End: 2026-08-21Updated: 2026-09-17